Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883758 | 1.00 | PARP1 (0.55) | PARP1AURKAALOX5FEN1KMT2A | |
| SCHEMBL3653358 | 0.78 | PARP1 (0.56) | PARP1AURKAALOX5DAOLDHA | |
| Hydrazine SCHEMBL26614899 | 0.75 | PARP1 (0.53) | PARP1AURKAALOX5KMT2ALDHA | |
| SCHEMBL29406967 | 0.75 | PARP1 (0.67) | PARP1AURKAFEN1KMT2AADORA2A | |
| SCHEMBL1441934 | 0.75 | PARP1 (0.67) | PARP1AURKAFEN1KMT2AADORA2A | |
| Hydrazine SCHEMBL7414290 | 0.74 | PARP1 (0.51) | PARP1AURKAALOX5KMT2ALDHA | |
| SCHEMBL6531057 | 0.71 | PARP1 (1.00) | PARP1AURKAFEN1KMT2AADORA2A | |
| SCHEMBL29349675 | 0.70 | ALOX5 (0.70) | PARP1ALOX5KMT2ADAOALDH1A1 | |
| SCHEMBL29766 | 0.70 | ALOX5 (0.70) | PARP1ALOX5KMT2ADAOALDH1A1 | |
| SCHEMBL23471322 | 0.70 | ALOX5 (0.35) | AURKAALOX5DAOAURKBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | claimed |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| WO-2025064210-A1 | INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) | BLOOD CELL TECHNOLOGIES, LLC (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2351744-B1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | SHIONOGI & CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8148395-B2 | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| EP-2351744-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | Shionogi & Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20090054478-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-4375467-A | 5-(Pyridinyl)-1H-pyrazolo[3,4-b] pyridines and their cardiotonic use | STERLING DRUG INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4361568-A | 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use | STERLING DRUG INC. (US) | 1982-11-30 | — | — | US | disclosed |
| EP-0063754-A1 | Pyrazolopyridine derivatives, and preparation, useful as cardiotonics | STERLING DRUG INC. (US) | 1982-11-03 | — | — | EP | disclosed |
| US-4265895-A | 1,2-Dihydro-5-pyridinyl-3H-pyrazolo[3,4-b]pyridin-3-ones and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4264603-A | 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation | STERLING DRUG INC. (US) | 1981-04-28 | — | — | US | disclosed |
| US-4264612-A | Lower-alkyl 2-halo-5-(pyridinyl)nicotinates, their preparation and use as cardiotonics | STERLING DRUG INC. (US) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, FFAR3 | PARP1 2951/4885AURKA 4569/4885ALOX5 225/4885 |
| US-20090054478-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LPL, CEL | PARP1 1716/4885AURKA 3520/4885ALOX5 257/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | PARP1 1519/4885AURKA 164/4885ALOX5 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.